BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9933852)

  • 1. Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients.
    Braga M; Gianotti L; Gentilini O; Vignali A; Corizia L; Di Carlo V
    Vox Sang; 1999; 76(1):38-42. PubMed ID: 9933852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery.
    Braga M; Gianotti L; Gentilini O; Vignali A; Di Carlo V
    Hepatogastroenterology; 1997; 44(15):685-90. PubMed ID: 9222672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
    Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
    Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery.
    Madi-Jebara SN; Sleilaty GS; Achouh PE; Yazigi AG; Haddad FA; Hayek GM; Antakly MC; Jebara VA
    J Cardiothorac Vasc Anesth; 2004 Feb; 18(1):59-63. PubMed ID: 14973801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery.
    Yoo YC; Shim JK; Kim JC; Jo YY; Lee JH; Kwak YL
    Anesthesiology; 2011 Nov; 115(5):929-37. PubMed ID: 22027622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
    Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin in anemia of prematurity.
    Whitehall JS; Patole SK; Campbell P
    Indian Pediatr; 1999 Jan; 36(1):17-27. PubMed ID: 10709119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.
    Parisotto R; Gore CJ; Emslie KR; Ashenden MJ; Brugnara C; Howe C; Martin DT; Trout GJ; Hahn AG
    Haematologica; 2000 Jun; 85(6):564-72. PubMed ID: 10870111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human erythropoietin and interleukin-3 on erythropoietic recovery from acute anemia.
    Rosen BS; Levine EA; Egrie JC; Sehgal LR; Greenberg R; Rosen AL; Levine HD; Gould SA
    Exp Hematol; 1993 Oct; 21(11):1487-91. PubMed ID: 8405228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
    Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
    Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
    Zehnder C; Blumberg A
    Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.